Wall Street Zen Upgrades BlossomHill Therapeutics (NASDAQ:BLSM) to Hold

BlossomHill Therapeutics (NASDAQ:BLSM) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other brokerages also recently weighed in on BLSM. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an “overweight” rating and a $28.00 target price on the stock. Zacks Research upgraded shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. HC Wainwright restated a “buy” rating on shares of BlossomHill Therapeutics in a report on Wednesday, September 30th. Leerink Partners boosted their price objective on shares of BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, September 21st. Finally, Lifesci Capital initiated coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, BlossomHill Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

BlossomHill Therapeutics Price Performance

BLSM opened at $14.63 on Friday. The stock has a market capitalization of $464.94 million and a price-to-earnings ratio of -1.67. The firm has a fifty day simple moving average of $19.16. BlossomHill Therapeutics has a 12-month low of $12.93 and a 12-month high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM) last issued its quarterly earnings results on Friday, September 18th. The company reported ($8.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($7.91). On average, equities analysts expect that BlossomHill Therapeutics will post -5.54 earnings per share for the current year.

Insider Activity

In other news, Director Bihua Chen bought 312,500 shares of the stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the director directly owned 3,614,034 shares of the company’s stock, valued at $57,824,544. This trade represents a 9.47% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John P. Schmid acquired 6,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the acquisition, the director directly owned 6,000 shares of the company’s stock, valued at $96,000. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.